Viewpoint

The Next Frontier for Transparency in Cancer Randomized Clinical Trials—Data and Safety Monitoring Boards

JAMA Oncology 10.1001/jamaoncol.2026.0035

March 19, 2026 at 11:00 AM EDT

Read the full article

This Viewpoint discusses increasing the transparency in cancer randomized clinical trials through the use of data and safety monitoring boards.

Corresponding Author: Ludovic Trinquart, PhD, Tufts Medical Center, 800 Washington St, Box 63, Boston, MA 02111 (ludovic.trinquart@tuftsmedicine.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks